Abstract: Dihydroxyaluminum aminoacetate, heavy magnesium carbonate, and aspirin tablets is a new combined aspirin preparation, each containing aspirin (81 mg), dihydroxyaluminum aminoacetate (11 mg), and heavy magnesium carbonate (22 mg). This study was conducted to evaluate the pharmacokinetic (PK) and bioequivalence in healthy Chinese subjects. This randomized, open-label, single-dose, 2-sequence, and 2-period crossover study included 78 healthy volunteers (fasting, n = 36; postprandial, n = 42). Blood samples were collected for PK analysis. Aspirin and salicylic acid concentrations in human plasma were determined by liquid chromatography-tandem mass spectrometry. Safety and tolerability were monitored. There were no significant differences between the test and reference formulations in maximum plasma concentration, area under the plasma concentration-time curve (AUC) from time 0 to time t, or AUC from time 0 to infinity. The 90% confidence intervals of the test and reference formulations of maximum plasma concentration, AUC from time 0 to time t, and AUC from time 0 to infinity were within the acceptable range (80%-125%) under fasting and postprandial conditions. All adverse events were mild and no serious adverse events were observed in the study. Both compounds were well tolerated in healthy Chinese volunteers.
(© 2024, The American College of Clinical Pharmacology.)
References: Liu S, Li Y, Zeng X, et al. Burden of cardiovascular diseases in China, 1990‐2016: findings from the 2016 global burden of disease study. JAMA Cardiol. 2019;4(4):342‐352.
The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2022: an updated summary. Biomed Environ Sci. 2023;36(8):669‐701.
Murphy E, Curneen JMG, McEvoy JW. Aspirin in the modern era of cardiovascular disease prevention. Methodist Debakey Cardiovasc J. 2021;17(4):36‐47.
Chubak J, Whitlock EP, Williams SB, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):814‐825.
Sutcliffe P, Connock M, Gurung T, et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS ONE. 2013;8(12):e81970.
Toruner M. Aspirin and gastrointestinal toxicity. Anadolu Kardiyol Derg. 2007;7(suppl 2):27‐30.
Triantafyllou K, Gkolfakis P, Gralnek IM, et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2021;53(8):850‐868.
Lotrionte M, Biasucci LM, Peruzzi M, et al. Which aspirin dose and preparation is best for the long‐term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta‐analysis. Prog Cardiovasc Dis. 2016;58(5):495‐504.
Veronese N, Stubbs B, Maggi S, et al. Low‐dose aspirin use and cognitive function in older age: a systematic review and meta‐analysis. J Am Geriatr Soc. 2017;65(8):1763‐1768.
McMahon GP, Kelly MT. Determination of aspirin and salicylic acid in human plasma by column‐switching liquid chromatography using on‐line solid‐phase extraction. Anal Chem. 1998;70(2):409‐414.
Kedir HM, Sisay EA, Abiye AA. Enteric‐coated aspirin and the risk of gastrointestinal side effects: a systematic review. Int J Gen Med. 2021;14:4757‐4763.
Angiolillo DJ, Bhatt DL, Lanza F, et al. Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. J Thromb Thrombolysis. 2020;49(3):337‐343.
Atar D, Sarkar S, Kolev E, et al. Randomized, open‐label, crossover trial comparing the pharmacokinetic profile of a novel oral aspirin solution and a chewed aspirin tablet. Int J Clin Pharmacol Ther. 2022;60(10):430‐438.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344‐e418.
Kanani K, Gatoulis SC, Voelker M. Influence of differing analgesic formulations of aspirin on pharmacokinetic parameters. Pharmaceutics. 2015;7(3):188‐198.
Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid‐aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48(4):554‐562.
Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs – a systematic review. Br J Clin Pharmacol. 2015;80(3):381‐388.
Endo H, Sakai E, Higurashi T, et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833‐838.
Koziolek M, Alcaro S, Augustijns P, et al. The mechanisms of pharmacokinetic food‐drug interactions – a perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31‐59.
Processing Request
No Comments.